Search results for: Oncology
Filter search results
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
…here, and on Shah, K.K., Mestre-Ferrandiz, J., Towse, A. and Smythe, E.N. (2013) A review of health technology appraisals: case studies in oncology. International Journal of Technology Assessment in Health Care. 29(1),…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…the EuroQol Group’s scientific research agenda for the coming year and plans for the EQ-5D-5L approach to measuring patient-reported outcomes of care. Health technology assessment affects patients’ access to oncology…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…600% from the 1970s[3] to the 2000s[4]. Second, success rates for clinical development are falling as tougher therapeutic areas are tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology. Success rates…
Shaheer Hassan
28 October 2025
…health economic modelling, and developing evidence-based approaches to improve HTA access. He has contributed to market access strategies for innovative oncology therapies, facilitated stakeholder engagement with key opinion leaders and…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…sharing” approach of the CDF to selected non-oncology drugs. The UK CDF remains the “poster child” for jurisdictions seeking to implement conditional coverage / reimbursement schemes. Risk sharing is the…
Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes
20 March 2012
…of life. At the Second Annual Oncology Market and Patient Access conference in January, Dr. Jorge Mestre-Ferrandiz presented preliminary results from OHE research in progress. It analyses appraisals of cancer…
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
4 October 2016, 11:00pm
…also developed the NICE scientific advice database. Prior to NICE Francois worked for the EMA for 15 years. His activities covered both pre- (registration of centrally authorised products in oncology,…
Aisha Aidarous
17 December 2025
…technology assessment. Her current research interests include economic evaluation of oncology interventions and exploring inequalities in healthcare decision-making and looks forward to expanding her expertise into additional areas of interest….
Dementia: The R&D Landscape
1 November 2015
…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…